2497 results about "Heterocyclic compound" patented technology

Provided herein are compounds having the following structure (I), wherein the substituents are as defined herein, compositions comprising a compound, and methods for modulating the activity of KRAS G12D.

The invention discloses an oxygen-containing heterocyclic compound salt, and a crystal form and application thereof. The oxygen-containing heterocyclic compound salt disclosed by the invention has a structure as shown in a formula II. The oxygen-containing heterocyclic compound salt and the crystal form thereof provided by the invention have one or more improved characteristics, which are represented by extremely high water solubility, and high dissolution rate and high solubility in physiological related medium simulated gastrointestinal fluid, so that the stability of the oxygen-containing heterocyclic compound under an oxidation condition is remarkably improved, and the stability of the oxygen-containing heterocyclic compound is improved. Low hygroscopicity and good crystal form stability are achieved, and oral absorption and long-term storage of the medicine are facilitated; and the preparation method is simple and suitable for industrial production. # imgabs0 #

Provided herein are compounds having the following structure (I), wherein the substituents are as defined herein, compositions comprising a compound, and methods for modulating the activity of KRAS G12D and / or G12V.

Provided is a compound useful as an active ingredient in a pharmaceutical composition for treating cancer.　The present inventors have examined a compound useful as an active ingredient in a pharmaceutical composition for cancer treatment, and have completed the present invention by finding that: a heterocyclic compound represented by formula (I) and formula (I-I) has excellent an action of inducing degradation of a mutant KRAS protein and a wild-type KRAS protein, and in particular, an action of inducing degradation of a KRAS protein having a G12C mutation, G12D mutation, G12V mutation, or G13D mutation; and said heterocyclic compound has mutant KRAS inhibition and the inhibitory activity of KRAS amplified by a wild-type KRAS gene, and in particular, inhibitory activity of KRAS having a G12C mutation, G12D mutation, G12V mutation, or G13D mutation. The heterocyclic compound according to the present invention or a salt thereof can be used as a therapeutic agent for cancer.

Provided is an antibody-drug conjugate for use in the treatment of cancer in which one or more KRAS mutants, particularly a KRAS G12V mutant, a KRAS G12D mutant, and a KRAS G12C mutant, are expressed. Also provided are a drug and a drug-linker conjugate for use in the antibody-drug conjugate.　The present inventors have produced an antibody-drug conjugate with which a heterocyclic compound represented by formula (II) and having an activity of inducing the decomposition of KRAS mutant proteins can be delivered to cancer in which EGFRs are expressed, the production being achieved by linking the compound to an anti-EGFR antibody. The present inventors have also discovered a drug-linker conjugate for use in the antibody-drug conjugate or a salt thereof. In cancer in which EGFRs are expressed, the antibody-drug conjugate induces the decomposition of one or more KRAS mutants, particularly a KRAS G12V mutant protein, a KRAS G12D mutant protein, and a KRAS G12C mutant protein, thereby inhibiting the KRAS mutants and exhibiting an anti-tumor effect.

A compound, as shown in Formula I, is a multi-heterocyclic compound. It has been verified that the compound provided by this invention integrates a novel compound targeting the calcitonin gene-related peptide (CGRP) based on ephedrine. Upon contact with the skin, due to photoactivated cell biological function regulation and the blocking effect of the multi-heterocyclic compound I structure on serotonin receptors, it achieves therapeutic effects on cutaneous vascular malformations and telangiectasia, improves the effectiveness of phototherapy in improving chronic cutaneous vascular diseases, and promotes skin wound healing.

The present invention provides a heterocyclic compound for inducing degradation of mutant KRAS protein, a pharmaceutically acceptable salt, a stereoisomer, a solvate or a prodrug thereof, as shown in formula (I), and the definition of each group in the formula is detailed in the specification. In addition, the invention also discloses a pharmaceutical composition containing the compound, and application of the pharmaceutical composition in preparation of a kit for treating cancers, immune diseases or prognosis evaluation of cancer patients. # imgabs0 #

The invention provides a boron-nitrogen heterocyclic compound as well as an intermediate and a preparation method thereof, the boron-nitrogen heterocyclic compound has a structure as shown in a general formula (1), and is prepared by taking compounds as shown in a formula A, a formula B and a formula C as intermediates. Compared with similar carbon skeleton molecules, the boron-nitrogen heterocyclic compound provided by the invention shows an excellent narrow-band luminescence property. The half-peak width of the emission spectrum of the boron-aza compound is as low as 6.4 nm, and meanwhile, the fluorescence quantum yield is as high as 97%.

The invention provides a pyrimidino heterocyclic compound as well as a pharmaceutical composition and application thereof. The invention provides a pyrimidino heterocyclic compound as shown in a formula I, and a stereoisomer, a tautomer, an atropisomer or a pharmaceutically acceptable salt of the pyrimidino heterocyclic compound. The compound disclosed by the invention has good proliferation inhibition activity on NCI-H358 cells, AsPC-1 cells and Capan-1 cells containing KRAS mutation, and has relatively weak proliferation inhibition activity on PC-9 cells wild in KRAS. # imgabs0 #

The present invention discloses a series of fluorine-substituted heterocyclic compounds, specifically, compounds represented by formula (XII) and pharmaceutically acceptable salts thereof. 【Chemical 1】 JPEG2025516367000403.jpg44170

The present invention relates to a heterocyclic compound represented by chemical formula 1, and an organic light-emitting device and a composition for an organic layer, each comprising same.

The present invention relates to a novel heterocyclic compound, which is a compound having FGFR3 protein activity. Specifically, the invention relates to a compound as shown in formula (I), or pharmaceutically acceptable salts, solvates, polymorphic substances or isomers thereof, and application of the compound in preparation of medicines for treating diseases related to FGFR3 (Fibroblast Growth Factor Receptor 3). # imgabs0 #

The present application discloses substituted polycyclic heterocycles compound of Formula (I), pharmaceutically acceptable salt and / or solvate and pharmaceutical compositions thereof useful in the treatment of proliferative disease or condition characterized by a dysregulation of the RAS-ERK pathway such as neoplasm disease or disorder, inflammatory disease or immune system disorder.

The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, esters, or prodrugs thereof:which inhibit Human Respiratory Syncytial Virus (HRSV) or Human Metapneumovirus (HMPV) inhibitors. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HRSV or HMPV infection. The invention also relates to methods of treating an HRSV or HMPV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

A salt of a substituted amino six-membered nitric heterocyclic compound, a crystal form thereof, a method for preparing same, and use thereof are provided. A dihydrochloride salt of a compound represented by formula (I) is a specific example. The salt can be prepared as a crystal form, the crystal form preferably having the following advantages: good solubility, low hygroscopicity, stable quality, and crystal form stability, thus being more easily developed into drugs as compared with the compound represented by formula (I) or other salts.

The invention belongs to the technical field of organic photoelectric materials, and particularly relates to a boron-nitrogen heterocyclic compound and an organic electroluminescent device thereof. The boron-nitrogen heterocyclic compound provided by the invention has relatively large steric hindrance, on one hand, molecular vibration is reduced, and the boron-nitrogen heterocyclic compound has relatively narrow half-peak width and can effectively improve the color purity of light emitted by a device; on the other hand, the distance between molecules is increased, the acting force between the molecules is weakened, quenching caused by aggregation is overcome, the luminous efficiency of the device can be improved, and the service life of the device can be prolonged.

The present invention discloses a non-aqueous electrolyte for a secondary battery and a secondary battery thereof, the electrolyte comprises an electrolyte salt, a non-aqueous solvent and an additive, the additive at least comprises: a nitrogen-containing heterocyclic compound as a first additive, a film-forming additive with a film-forming potential of less than 1.5 V (vs. Li + / Li) as a second additive, the specific structure of the additive is shown in the specification. The nitrogen-containing heterocyclic compound and the film-forming additive with the film-forming potential lower than 1.5 V (vs.Li < + > / Li) are combined for use, and the nitrogen-containing heterocyclic compound and the film-forming additive are regulated in a specific content ratio range to fully generate a synergistic effect, so that water catching and acid inhibition can be effectively realized, decomposition and gas production can be effectively inhibited at high temperature and high voltage, the stability of the electrolyte is greatly improved, and the service life of the electrolyte is prolonged. And an SEI film with excellent ion transmission capability and structure / thermal stability can be formed on the surface of the electrode, so that the first efficiency of the battery is effectively improved, and the low-temperature performance and the cycle performance of the battery are further improved.

The invention provides a carbazole-containing heterocyclic compound and an organic electroluminescent device thereof, and relates to the technical field of organic electroluminescent materials. The carbazole-containing heterocyclic compound provided by the invention has relatively high polarizability, is beneficial to improving the refractive index, and can reduce the total reflection phenomenon during light emission of the device and effectively improve the light extraction efficiency of the device when being applied to a covering layer of the organic electroluminescent device; and meanwhile, the compound has relatively high glass transition temperature and good film-forming property, and can isolate moisture and oxygen, so that the luminous efficiency and the service life of the organic electroluminescent device are further improved and prolonged. The preparation method of the compound is simple, raw materials are easy to obtain, and the compound can be widely applied to the fields of organic thin film transistors, panel display and the like and has good application effects and industrialization prospects.

The present invention relates to the technical field of pharmaceutical chemistry, and provides a heterocyclic compound and a pharmaceutical use thereof. The structure of the heterocyclic compound is as shown in formula II. The compound of the present invention has high-efficiency sedative, hypnotic and / or anesthetic effects, can control status epilepticus, and also has an analgesic effect, providing a new choice for clinical preparation of a drug having the analgesic effect, a drug having the anesthetic, sedative, and hypnotic effects and / or capable of controlling status epilepticus, and a drug having both the anesthetic, sedative, and hypnotic effects and / or capable of controlling status epilepticus and also having the analgesic effect.

The invention discloses a nitrogen-containing heterocyclic ring compound as well as a preparation method and application thereof, and particularly relates to a nitrogen-containing heterocyclic ring compound as shown in a general formula (I), or pharmaceutically acceptable salts thereof, or enantiomers, diastereoisomers, tautomers, torsion isomers, solvates, polymorphic substances or prodrugs thereof, and a preparation method and pharmaceutical application thereof. Wherein the definition of each group is described in the specification. # imgabs0 #

The invention discloses a novel substituted heterocyclic compound with GSPTs / CK1a double-target degradation activity, and particularly discloses a compound which has the GSPTs / CK1a double-target degradation activity and is shown in a formula (I) or pharmaceutically acceptable salt, solvate, hydrate, isotope substitute or isomer of the compound. The compound can be used for preventing or treating diseases related to GSPTs / MYC / CK1a / WNT targets or signal pathways.

The present disclosure provides compounds of Formula (I), useful for the activation of Triggering Receptor Expressed on Myeloid Cells 2 ("TREM2"). This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a neurodegenerative disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula (I).

The invention provides an adhesive based on a lipoic acid compound and a nitrogen heterocyclic compound as well as a preparation method and application of the adhesive, and belongs to the field of material chemistry. The adhesive disclosed by the invention is prepared from a lipoic acid compound, a nitrogen heterocyclic compound and absolute ethyl alcohol, the azacyclo-compound is at least one of an azacyclo-naphthenic compound or an azacyclo-crown ether compound. The adhesive disclosed by the invention is simple in raw material composition and preparation method, and the obtained adhesive has the advantages of high bonding strength, excellent underwater bonding performance, wide applicable materials, high bonding speed, environment friendliness, recoverable raw materials and the like, and shows huge application potential.

The present invention relates to a heterocyclic compound for inhibiting PRMT5 activity, and a stereoisomer thereof, or a pharmaceutically acceptable salt thereof. The heterocyclic compound for inhibiting PRMT5 activity has a structure as represented by formula (I). Further provided in the present invention are a composition containing the compound and the use thereof as a PRMT5 inhibitor.